Search clinical trials for: CD79b CAR-T Cells

Total 2195 results

Fuda Cancer Hospital, Guangzhou

Withdrawn

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Breast Cancer

China
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma

Spain
Zhu Xiaofan

Recruiting

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

B Lymphoblastic Lymphoma | B Lymphocytic Leukemia

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Acute T-lymphoblastic Leukemia | Acute T-lymphoblastic Lymphoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

GD2 Positive Glioma | CAR-T Cell Immunotherapy

China
Hrain Biotechnology Co., Ltd.
Ruijin Hospital

Not yet recruiting

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Acute Lymphoblastic Leukemia

China
RenJi Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy

China
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

CAR-T

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Autoimmune Diseases | Lupus Nephritis | Immune Nephritis

China
Precision BioSciences, Inc.

Recruiting

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Hematologic Malignancy | CD19 Expressing Malignancies

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Eutilex

Recruiting

To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307

Advanced Hepatocellular Carcinoma

Korea, Republic of
National University Hospital, Singapore

Recruiting

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy Syndrome | Refractory Leukemia

Singapore
National University Hospital, Singapore

Recruiting

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. (ALaCART)

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy Syndrome

Singapore
The Affiliated Hospital of Xuzhou Medical University
Xuzhou Medical University

Recruiting

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

Immunotherapy

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Hepatocellular Carcinoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

CAR-T Cell Immunotherapy | EphA2 Positive Malignant Glioma

China
First Affiliated Hospital of Chengdu Medical College

Unknown

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (CARTEPC)

Gastric Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Esophageal Carcinoma | Hepatic Carcinoma

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Central Nervous System Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
University of Pennsylvania

Completed

CART-19 for Multiple Myeloma

Multiple Myeloma

United States
Laura Johnston
National Institutes of Health (NIH)

Completed

Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD

Graft Versus Host Disease | Allogeneic Hematopoietic Cell Transplant Recipient

United States
Mitchell Horwitz, MD

Completed

Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

Hematological Malignancies

United States
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Fuda Cancer Hospital, Guangzhou
Jinan University Guangzhou

Completed

Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

Lung Cancer

China
University of Pennsylvania
University of California, San Francisco

Terminated

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

Patients With Residual or Reccurent EGFRvIII+ Glioma

United States
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Shanghai Cell Therapy Group Co.,Ltd

Recruiting

An Exploratory Study by Fast CAR T Cells

Solid Tumor

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

4SCAR19U T Cells Targeting B Cell Malignancies

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
CARsgen Therapeutics Co., Ltd.
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Active, not recruiting

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Multiple Myeloma

China
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Henan Cancer Hospital

Unknown

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)

Relapsed and Refractory Multiple Myeloma

China
Uppsala University
Karolinska University Hospital; Uppsala University Hospital; AFA Insurance; Swedish...

Completed

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

B Cell Lymphoma | B Cell Leukemia

Sweden
Pinze Lifetechnology Co. Ltd.
Chinese Academy of Sciences; Navy General Hospital, Beijing

Unknown

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Antonio Pérez Martínez

Recruiting

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma (CAR4SAR)

Advanced Sarcoma

Spain
Autolus Limited

Enrolling by invitation

Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified

Multiple Myeloma | DLBCL | T Cell Lymphoma | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy | ALL, Adult and Pediatric

United Kingdom
Marcela V. Maus, M.D.,Ph.D.

Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
RenJi Hospital
AbelZeta Pharma Inc.

Recruiting

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (CAR-AID)

Systemic Lupus Erythematosus (SLE) | Neuromyelitis Optica Spectrum Disorders | Immune-Mediated Necrotizing Myopathy | Multiple Sclerosis-Relapsing-Remitting

China
Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Recruiting

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

B-ALL

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
Second Affiliated Hospital of Guangzhou Medical...
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Zhaotai InVivo... and other collaborators

Recruiting

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

Hepatocellular Carcinoma | CAR | Immunotherapy | Squamous Cell Lung Cancer | GPC3 Gene Inactivation | T Cell

China
Memorial Sloan Kettering Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Active, not recruiting

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Refractory | Relapsed

United States
Sichuan University

Active, not recruiting

EpCAM CAR-T for Treatment of Advanced Solid Tumors

Breast Cancer Recurrent | Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M) | Gastric Cancer With Metastasis

China
University of Pennsylvania

Terminated

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

Breast Cancer | Malignant Melanoma

United States
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China

Search clinical trials for: CD79b CAR-T Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations